Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966467 · ClinicalTrials.gov registry record
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
A clinical trial of Neuromyelitis Optica Spectrum Disorder and NMOSD, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 122
- Enrollment target
- 20
- Study locations
NCT05966467: Recruiting study of Neuromyelitis Optica Spectrum Disorder and NMOSD, sponsored by Alexion Pharmaceuticals.
NCT05966467 is a study of Neuromyelitis Optica Spectrum Disorder and NMOSD that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 122 participants, above the 46-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (165% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966467, a study of Neuromyelitis Optica Spectrum Disorder and NMOSD, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 122 participants
- Enrollment target
- 20
- Study locations
Study Summary
Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.
Primary Outcome
The ARR is defined as the total number of relapses divided by the total number of participant-years.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Buenos Aires
- Clinical Trial Site - Beijing
- Clinical Trial Site - Guangzhou
- Clinical Trial Site - Henan
- Clinical Trial Site - Shanghai
- Clinical Trial Site - Sichuan
- Clinical Trial Site - Wuhan
- Clinical Trial Site - Dresden
- Clinical Trial Site - Essen
- Clinical Trial Site - München
District of Columbia
- Clinical Trial Site - Washington D.C.
Massachusetts
- Research Site - Boston
North Carolina
- Clinical Trial Site - Chapel Hill
Ohio
- Clinical Trial Site - Columbus
Texas
- Clinical Trial Site - Plano
Wisconsin
- Clinical Trial Site - Milwaukee
British Columbia
- Clinical Trial Site - Burnaby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2030-03-01 |
What NCT05966467 shows while recruiting
NCT05966467 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 46-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (165% higher).
The record links to 3 conditions, with Neuromyelitis Optica Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT05966467 names 20 study sites across 8 states, led by Other, District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05966467 about?
NCT05966467 is a clinical study titled "Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies". Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality ...
What is the current status of trial NCT05966467?
This trial is currently recruiting. The enrollment target is 122 participants. The study started on 2024-02-01. Estimated completion is 2030-03-01.
What conditions does trial NCT05966467 study?
This clinical trial studies the following conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ Nmosd.
Who is sponsoring clinical trial NCT05966467?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966467 being conducted?
This trial has 20 study locations across District of Columbia, Massachusetts, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
RECRUITING · Phase 3
-
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
RECRUITING
-
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
RECRUITING · Phase 2
-
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
RECRUITING · Phase 2
-
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
ACTIVE NOT RECRUITING · Phase 4
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI